Erratum: Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives.

[This corrects the article on p. 22 in vol. 20, PMID: 26904465.].

In the article titled, “Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives” published in pages 22-31, issue 1, vol. 20 of Indian Journal of Endocrinology and Metabolism [1], the references 30 and 31 in the reference list are written incorrectly.

The correct references are following:

Reference 30: Rosenstock J, Jelaska A, Frappin G, Salsali A, Kim G, Woerle HJ, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care 2014;37:1815-23.

Reference 31: Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl UC, Woerle HJ; EMPA-REG BASALTM Trial Investigators. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: A 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2015;17:936-48.

The references 30 and 31 cited in the article Tables 2 and 3 should be renumbered accordingly.